{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-030505","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.863979+00:00","generated_at":"2026-06-04T22:30:29.333219+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PepGen receives FDA orphan drug and rare pediatric disease designations for DMD candidate PGN-EDO51","bullets":["FDA granted orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapy for DMD.","PGN-EDO51 targets DMD patients whose mutations are amenable to exon 51 skipping approach.","Ongoing CONNECT1 Phase 2 trial; CONNECT2 Phase 2 enrollment expected later in 2024.","Orphan designation offers 7-year U.S. exclusivity plus tax credits and fee benefits upon approval.","Rare pediatric disease designation may yield a priority review voucher for a future product."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-030505","json":"https://secwatch.observer/filing/0000950170-24-030505.json","markdown":"https://secwatch.observer/filing/0000950170-24-030505.md","text":"https://secwatch.observer/filing/0000950170-24-030505.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024030505/0000950170-24-030505-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024030505/pepg-20240313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:30:29.333219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}